Prevention & lipidsResearch article
Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association
- Modelling study (economic projection; AHA Presidential Advisory)
- nationally representative US data
- human capital approach for productivity losses
Authors' conclusion
The economic burden of cardiovascular risk factors and overt cardiovascular disease in the United States is projected to increase substantially in the coming decades.
Study context
- Population
- US adults; cardiovascular risk factors (hypertension, DM, hypercholesterolemia) and conditions (CHD, stroke, HF, AF)
- Outcome
- Health care costs attributable to CV risk factors and conditions, and productivity losses from CV conditions
- Follow-up
- 2020 to 2050
Main finding
As reported in the abstract
Health care costs of CV risk factors, projected (2020 → 2050; to triple)
$400 billion to $1344 billion
Health care costs of CV conditions, projected (2020 → 2050; to almost quadruple)
$393 billion to $1490 billion
Productivity losses from CV conditions, projected increase (2020 → 2050)
54%, from $234 billion to $361 billion
Further findings
US adults receiving care for a CV risk factor or condition · 2020
- Proportion of US adults
- 1 in 3
Cost increase by condition
- Stroke projected to account for the largest absolute increase in costs
Relative cost increase by population
- Asian American population
- 497%
- Hispanic American population
- 489%
- reflect projected increases in the size of these populations
Original publication
Summarised from the published abstract; every number is checked against it